journal article·2025-10Open access

Biomimetic “Trojan Horse” delivery of traditional Chinese medicine with immunogenic hybrid vesicles of bacterial outer membrane and tumor cell membrane for synergistic chemo-immunotherapy of liver cancers

Zhaoyan Zhao, Lanxin Luo, Zhongting Wang, Bing Guo, Changjun Gao

Abstract

ABSTRACT Nowadays it is a big challenge to treat liver cancer, owing to the lack of efficient therapeutic paradigms. Currently, the first-line chemotherapy and immunotherapy often suffer from drug resistance, and severe side effects. The emerging Chinese medicine of Glycyrrhizic acid (GA) shows promise for liver cancer therapy, but often exhibits substantial toxicity and side effects. To explore efficient liver cancer treatment paradigms, herein, a “Trojan Horse” strategy is developed using biomimetic nanoplatform to deliver GA for dual chemo-immunotherapy of liver cancer. The nanoplatform (GANPs@COP) is composed of PLGA-coated GANP (GANPs@P) as the core, and hybrid vesicle (CO) of tumor cell membranes (CMVs) and bacterial outer membranes (OMVs) as the shell. In the nanoplatform, CMVs and OMVs contribute to tumor targeting and immunogenicity, respectively, while GA executes chemotherapy to locally destruct primary tumor cells. The nanoplatform synergistically ablate tumors by modulating tumor immunosuppressive microenvironment, promoting secretion of inflammatory cytokines, repolarizing macrophage M2 to M1, maturating dendritic cells, and eliciting CD8 + T cell infiltration, with significantly boosted therapeutic outcomes. Importantly, the nanoplatform even constructs immune memory effects for long-term tumor inhibition. This study offers a novel perspective for the combined application of traditional Chinese medicine therapy and immunotherapy of liver cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer Research and Treatments · Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (64)

Show source-provided references
1. Recent advances in the management of hepatocellular carcinoma10.3350/cmh.2023.0125 ↗
2. Epidemiology and surveillance for hepatocellular carcinoma: new trends10.1016/j.jhep.2019.08.025 ↗
3. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
4. Global burden of primary liver cancer in 2020 and predictions to 204010.1016/j.jhep.2022.08.021 ↗
5. RNA nanotherapeutics for hepatocellular carcinoma treatment10.7150/thno.102964 ↗
6. Modern therapeutic approaches for the treatment of malignant liver tumours10.1038/s41575-020-0314-8 ↗
7. Insights into the history and tendency of liver transplantation for liver cancer: a bibliometric-based visual analysis10.1097/JS9.0000000000000806 ↗
8. Guidelines for the Diagnosis and treatment of primary liver cancer (2022 edition)10.1159/000530495 ↗
9. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer10.1016/j.cmet.2022.05.003 ↗
10. Emerging evidence-based role for external-beam radiation therapy in hepatocellular carcinoma10.1016/S2468-1253(24)00267-X ↗
11. Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomised phase 2 trial10.1016/S2468-1253(25)00024-X ↗
12. Lipoic acid/Choline Ionic Liquid enhanced intratumoral heat/mass transfer for suppressing thermo-mediated tumor relapse and metastasis10.1002/adma.202415157 ↗
13. Tailored Liposomal Nanomedicine suppresses incomplete radiofrequency ablation-induced tumor relapse by reprogramming antitumor immunity10.1002/adhm.202403979 ↗
14. Challenges in liver cancer and possible treatment approaches
15. Nanomedicine-unlocked radiofrequency dynamic therapy dampens incomplete radiofrequency ablation-arised immunosuppression to suppress cancer relapse10.1016/j.biomaterials.2025.123087 ↗
16. The gut microbiota: an emerging modulator of drug resistance in hepatocellular carcinoma10.1080/19490976.2025.2473504 ↗
17. Immunotherapy for hepatocellular carcinoma10.1016/j.canlet.2019.12.002 ↗
18. Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science10.1002/cam4.2108 ↗
19. Regulatory mechanisms of signaling pathways in liver cancer treatment with traditional Chinese medicine10.1016/j.jep.2025.119386 ↗
20. Natural products in licorice for the therapy of liver diseases: progress and future opportunities10.1016/j.phrs.2019.04.025 ↗
21. Glycyrrhizic acid formulated in Hydrotalcite nanocarriers intended to act as a Hepatoprotective agent10.1208/s12248-024-00986-8 ↗
22. A randomized controlled trial of glycyrrhizin Plus tenofovir vs. Tenofovir in chronic hepatitis B with severe acute exacerbation10.1038/ctg.2017.29 ↗
23. Glycyrrhizic acid-lipid framework Nanovehicle loading triptolide for combined immunochemotherapy10.1021/acsami.3c08003 ↗
24. Co-delivery of glycyrrhizin and doxorubicin by alginate nanogel particles attenuates the activation of macrophage and enhances the therapeutic efficacy for hepatocellular carcinoma10.7150/thno.35972 ↗
25. Effects of glycyrrhizin in a mouse model of lung Adenocarcinoma10.1159/000467897 ↗
26. A metal ions-mediated natural small molecules carrier-free injectable hydrogel achieving laser-mediated photo-Fenton-like anticancer therapy by synergy apoptosis/cuproptosis/anti-inflammation
27. Toxicological effects of Glycyrrhiza glabra (licorice): a review10.1002/ptr.5893 ↗
28. Glycyrrhizic acid-based carbonized dots boost antiviral activity against influenza A virus via multisite inhibition mechanisms10.1021/acsami.2c21319 ↗
29. Harnessing engineered immune cells and bacteria as drug carriers for cancer immunotherapy10.1021/acsnano.2c07607 ↗
30. Win-win integration of genetically engineered cellular nanovesicles with high-absorbing multimodal phototheranostic molecules for boosted cancer photo-immunotherapy10.1002/adma.202416590 ↗
31. CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype10.1186/s13046-025-03286-x ↗
32. Immunosuppressive microenvironment of liver restrains chemotherapeutic efficacy in triple-negative breast cancer10.1136/jitc-2024-010871 ↗
33. Nanoparticle drug delivery systems and their applications as targeted therapies for triple negative breast cancer10.1016/j.pmatsci.2023.101070 ↗
34. Nanomedicine tumor targeting10.1002/adma.202312169 ↗
35. Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs10.7150/thno.39434 ↗
36. Extracellular vesicles as a next-generation drug delivery platform10.1038/s41565-021-00931-2 ↗
37. Leveraging nature's nanocarriers: translating insights from extracellular vesicles to biomimetic synthetic vesicles for biomedical applications10.1126/sciadv.ads5249 ↗
38. Engineering autologous tumor cell vaccine to locally mobilize antitumor immunity in tumor surgical bed10.1126/sciadv.aba4024 ↗
39. Personalized cancer immunotherapy via transporting endogenous tumor antigens to lymph nodes mediated by nano Fe(3) O(4)10.1002/smll.201870173 ↗
40. Orchestration of biomimetic membrane coating and nanotherapeutics in personalized anticancer therapy10.1039/D0BM01617A ↗
41. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines10.1126/scitranslmed.abc2816 ↗
42. Pleiotropy of biomineralized bacterial outer membrane vesicles in modulating immune systems for liver cancer therapy10.1016/j.cej.2024.155592 ↗
43. Bioengineered bacterial vesicles as biological nano-heaters for optoacoustic imaging10.1038/s41467-019-09034-y ↗
44. The outer membrane is an essential load-bearing element in Gram-negative bacteria10.1038/s41586-018-0344-3 ↗
45. An OMV-based Nanovaccine as antigen presentation signal enhancer for cancer immunotherapy10.1002/adma.202413392 ↗
46. Composition and functions of bacterial membrane vesicles10.1038/s41579-023-00875-5 ↗
47. Engineered bacterial outer membrane vesicles-based doxorubicin and CD47-siRNA Co-delivery nanoplatform Overcomes immune resistance to potentiate the immunotherapy of Glioblastoma
48. Bacterial derivatives mediated drug delivery in cancer therapy: a new generation strategy10.1186/s12951-024-02786-w ↗
49. Bacterial outer membrane vesicle-cancer cell hybrid membrane-coated nanoparticles for sonodynamic therapy in the treatment of breast cancer bone metastasis10.1186/s12951-024-02619-w ↗
50. Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy10.1002/jev2.12120 ↗
51. Hybrid vesicles based on autologous tumor cell membrane and bacterial outer membrane to enhance innate immune response and personalized tumor immunotherapy10.1021/acs.nanolett.1c02482 ↗
52. Tumour-derived extracellular vesicle membrane hybrid lipid nanovesicles enhance siRNA delivery by tumour-homing and intracellular freeway transportation10.1002/jev2.12198 ↗
53. PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration10.1126/sciadv.adt3044 ↗
54. BASTA, a simple whole-blood assay for measuring β cell antigen-specific CD4(+) T cell responses in type 1 diabetes10.1126/scitranslmed.adt2124 ↗
55. The intrinsic expression of NLRP3 in Th17 cells promotes their protumor activity and conversion into Tregs10.1038/s41423-025-01281-y ↗
56. Linking macrophage metabolism to function in the tumor microenvironment10.1038/s43018-025-00909-2 ↗
57. Tumor-associated macrophages in liver cancer: from mechanisms to therapy10.1002/cac2.12345 ↗
58. Optical molecular imaging technology and its application in precise surgical navigation of liver cancer10.7150/thno.102671 ↗
59. The immunological and metabolic landscape in primary and metastatic liver cancer10.1038/s41568-021-00383-9 ↗
60. Arneth · Medicina (Kaunas, Lithuania) · 2019 · 56 · 1510.3390/medicina56010015 ↗
61. The protein circPETH-147aa regulates metabolic reprogramming in hepatocellular carcinoma cells to remodel immunosuppressive microenvironment10.1038/s41467-024-55577-0 ↗
62. In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity
63. Memory T-cell heterogeneity and terminology10.1101/cshperspect.a037929 ↗
64. Memory T cells: strategies for optimizing tumor immunotherapy10.1007/s13238-020-00707-9 ↗